First 18F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3593-3606

  Schottelius, Margret ^a   Poethko, Thorsten ^a   Herz, Michael ^a   Reubi, Jean Claude ^b   Kessler, Horst ^c   Schwaiger, Markus ^a   Wester, Hans Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 FLUOROBENZALDEHYDE F 18; CELLOBIOSE; CELLOBIOSE FLUOROBENZALDEHYDE 3 TYROSINE OCTREOTATE F 18; FLUORINE 18; GLUCOSE; GLUCOSE FLUOROBENZALDEHYDE 3 TYROSINE OCTREOTATE F 18; GLUCOSE LYSINE FLUOROPROPIONYL 3 TYROSINE OCTREOTATE F 18; IODINE 125; OXIME; RADIOISOTOPE; SOMATOSTATIN RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CHO CELL; DRUG DISTRIBUTION; DRUG SELECTIVITY; FEMALE; FLUORINATION; INTERNALIZATION; INTESTINE; ISOTOPE LABELING; KIDNEY; LIVER; MOUSE; MUSCLE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLYCOSYLATION; INHIBITORY CONCENTRATION 50; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; NEOPLASMS; OXIMES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RECEPTORS, SOMATOSTATIN; TIME FACTORS; TISSUE DISTRIBUTION; TRANSFECTION;

EID: 2542544479     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0359     Document Type: Article

References (56)

1. 86Y-DTPA-octreotide. Nucl Med Biol 1997;24:275-86.
2. 86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue. Eur J Nucl Med 1999;26:358-66.
3. 3-octreotide (SMT487) -a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid coinfusion. Eur J Nucl Med Mol Imaging 2003;30:510-8.
4. 3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 1999;5:3608-16.
5. 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 1999;42:1341-7.
6. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213-21.
7. Froidevaux S, Eberle AN, Christe M, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002;98:930-7.
8. Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751-7.
9. 3-octreotide: First results in patients with meningiomas. J Nucl Med 2001;42:1053-6.
10. 3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 2002;29:147-57.
11. 111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002;13:530-41.
12. Lundqvist H, Tolmachev V. Targeting peptides and positron emission tomography. Biopolymers (Pept Sci) 2002;66:381-92.
13. Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med 2001;28:929-38.
14. 1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol 1994;21: 819-25.
15. Hostetler ED, Edwards WB, Anderson CJ and Welch MJ. J Labelled Compd. Radiopharm 1999;42 (Suppl 1): 720-2.
16. 18F-labeled sstr-binding SPECT/PET tracers with improved biodistribution. J Labeled Compd Radiopharm 1999;42:549-51.
17. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61: 1781-5.
18. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-36.
19. 3-octreotide by conjugation with carbohydrates. Bioconjug Chem 2002;13:1021-30.
20. Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydra-tion on the pharmacokinetics. Eur J Nucl Med Mol Imaging 2002;29:28-38.
21. Vaidyanathan G, Friedman HS, Affleck DJ, Schottelius M, Wester HJ, Zalutsky MR. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin Cancer Res 2003;9:1868-76.
22. 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med 2003;30:117-22.
23. Wester HJ, Hamacher K, Stöcklin G. A comparative study of N. C. A. fluorine-18-labeling of proteins via acylation and photochemical conjugation Nucl Med Biol 1996;23:365-72.
24. 18F]fluorobenzoate. Int J Rad Appl Instrum 1992;(B 19):275-81.
25. Fredriksson A, Ekberg K, Ingvar M, Johansson BL, Wahren J, Stone-Elander S. In vivo biodistribution and pharmacokinetics of (18)F-labeled human C-peptide: evaluation in monkeys using positron emission tomography. Life Sci 2002;71:1361-70.
26. Bergmann R, Scheunemann M, Heichert C, et al. Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs. Nucl Med Biol 2002;29:61-72.
27. Kurth M, Pelegrin A, Rose K, et al. Site-specific conjugation of a radioiodinated phenethylamine derivative to a monoclonal antibody results in increased radioactivity localization in tumor. J Med Chem 1993;36:1255-61.
28. Thumshim G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry Eur J 2003;9:2717-2725.
29. Elofsson M, Walse B, Kihlberg J. Building blocks for glycopeptide synthesis: Glycosylation of 3-mercapropropionic acid and fmoc amino acids with unprotected carboxyl groups. Tetrahedron Lett 1991;32:7613-6.
30. Shin I, Park K. Solution phase synthesis of aminooxy peptoids in the C to N and N to C directions. Org Lett 2002;4:869-72.
31. Herzig J, Nudelman A, Gottlieb HE, Fisher B. Studies in sugar chemistry. 2. A simple method for O-deacylation of polyacylated sugars. J Org Chem 1986;51:727-30.
32. Albert R, Marbach P, Bauer W, et al. SDZ CO 611: A highly potent glycosylated analog of somatostatin with improved oral acitivity Life Sci 1993;53:517-25.
33. Bergmann ED, Blank I. Studies on organic fluorine compounds part I: Some esters of monofluoroacetic acid and related compounds. J Am Chem Soc 1953;75:3786.
34. 18F]fluorobenzyl halides. Appl Radiat Isotopes 2000;52:87-92.
35. Buchwald P, Bodor N. Octanol-water partition of nonzwitterionic peptides: predictive power of a molecular size-based model. Proteins: Structure, Function and Genetics 1998;30:86-99.
36. Reubi JC, Schär JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur. J Nucl Med 2000;27:273-82.
37. Viguerie N, Tahari-Jouti N, Esteve JP, et al. Functional somatostatin receptors on a rat pancreatic acinar cell line. Am J Physiol 1988; 255:G113-20.
38. Buré, C. Lelièvre D, Delmas A. Identification of by-products from an orthogonal peptide ligation by oxime bonds using mass spectrometry and tandem mass spectrometry. Rapid Commun Mass Spectrom 2000; 14:2158-64.
39. 13C-NMR-Untersuchungen an Mutarotationsgemischen C-6- und C-4- sowie C-6-modifizierter Amadoriverbindungen Liebigs Ann Chem 1978;2099-104.
40. Elofsson M, Roy S, Walse B, Kihlberg J. Solid-phase synthesis and conformational studies of glycosylated derivatives of helper-T-cell immunogenic peptides from hen-egg lysozyme. Carbohydrate Res 1993; 246:89-103.
41. Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTRI-5): Subtype selective internalization or upregulation. Endocrinology 1996;137:4046-9.
42. Froidevaux S, Hintermann E, Török M, Mäcke HR, Beglinger C, Eberle AN. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res 1999;59:3652-7.
43. 3]octreotide by mouse and human pituitary tumor cells: Increase by unlabeled octreotide. Endocrinology 1995;136:3698-706.
44. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437-41.
45. 3]octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radioguided surgery. Proc Assoc Am Physicians 1999;111:63-9.
46. 2 receptors and associated agonists. Biochem J 1998;336:291-8.
47. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indiurn-111-diethylene-triaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997;57:659-71.
48. 1-Octreotide in vivo. Bioconjugate Chem 1998;9:662-70.
49. 131I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. Bioconjugate Chem 2003;14:331-41.
50. Froidevaux S, Heppeler A, Eberle AN, et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 2000;141:3304-12.
51. Bokum AMC, Rosmalen JGM, Hofland LJ, Krenning EP, van Hagen PM, Breeman WAP. Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity. Nucl Med Commun 2002;23:1009-17.
52. Kraus J, Wöltje M, Schönwetter N, Höllt V. Alternative promotor usage and tissue specific expression of the mouse somatostatin receptor 2 gene. FEBS Lett 1998;428:165-70.
53. 3-octreotate A new somatostatin analog with improved target tissue uptake Nucl Med Biol 1999;26:267-73.
54. Behr TM, Goldenberg DM, Becker WS. Reducing the renal uptake of radiolabelled antibody fragments and peptides for diagnosis and therapy: present status and future limitations. Eur J Nucl Med 1998;25:201-12.
55. de Jong M, Rolleman El, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388-92.
56. 111In-DTPA-conjugated peptides. Nucl Med Biol 2001;28:761-8.